NextCell invited speaker at the Advanced Therapy Congress in London

Today, NextCell Pharma AB’s CEO, Dr. Mathias Svahn, is presenting clinical data from the ProTrans-1 and ProTrans-2 diabetes studies. Ranked as one of Europe's most important events in the field of advanced therapies, the ExCel event brings together leading players in the pharmaceutical industry to provide information on the latest technologies attracting more than 2,000 visitors. The scope of the summit is to explore, define and tackle the challenges of, and patient access to ATMPs (Advanced Therapy Medicinal Products), as the field moves into an exciting 2022.

NextCell has developed an allogeneic mesenchymal stromal cell product for treatment of diabetes type-1 using its patent pending selection algorithm. The cell therapy, manufactured using the selection algorithm, has, as previously reported, shown excellent safety and efficacy in the ProTrans-1 and ProTrans-2 clinical studies in individuals with type 1 diabetes.

The intriguing data from the clinical trials and NextCell’s ProTrans proprietary cells have been recognized in this space. High potency and immunomodulatory function are key attributes of ProTrans and characterise ProTrans as an effective cell therapy. NextCell has incorporated the assessment early in the manufacturing process by applying multiple functional and potency assays in the selection of cells and donors.

“It is exciting to present ProTrans data to our colleagues in real life”, says Mathias Svahn.

Dr. Svahn will give a 30-minute lecture covering both ProTrans-1 and ProTrans -2 data, on October 6^th at the ExCel congress in London. The session will be chaired by Dr. Moshe Israeli, Medical Director, Rabin Medical Center.

För further information, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO

Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com

Home pages:

NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk

About NextCell Pharma AB

NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.

FNCA Sweden AB is assigned as Certified Adviser, +46 8 528 00 399, info@fnca.se.